CHRISTUS Stehlin Foundation is dedicated to patient-focused research, limiting investigations to human cancers. Because of their focus on shortening the time from the test tube to treatment, thousands of cancer patients are alive today as a result of the Foundation’s work.
The Foundation’s founder, Dr. John S. Stehlin, Jr., was a visionary surgical oncologist who saw beyond existing protocols. His drive was to improve collaboration between cancer patients, the physicians providing treatment, and the scientists working to combat the disease. He worked as both researcher and physician until his retirement in 2002.
Dr. Stehlin stressed the importance of hope, faith, laughter, and love in patient recovery. In 1980, he established the ”Living Room” on his oncology unit at St. Joseph’s Hospital, where patients could see family and friends, read, watch television, and generally find relief from the hospital atmosphere. The concept has been adopted by cancer centers worldwide.
Working with a small staff and limited facilities, the Foundation was the first to develop and apply many cancer therapies now recognized as the “treatment of choice.”
The Foundation has been widely recognized in the scientific world as a pioneer in cancer research. Its breakthroughs have been documented in more than 500 scientific and medical journal articles. Some examples:
CZ48 Clinical Trials – Phase I human trials of this new chemotherapy agent, a product of the Foundation’s cancer drug development program, are underway at The UT Health Science Center-San Antonio Cancer Center and the University of New Mexico Cancer Center. CZ48, a derivative of camptothecin, has shown remarkable anticancer activity against breast, lung, colon, pancreas, and bladder carcinomas, melanomas, and DSRCT sarcomas in laboratory studies.
Prostate Cancer Cell Model – Stehlin scientists are collaborating with Baylor College of Medicine physicians to create a broad line of tissue culture cell lines and xenografts of human prostate cancer. The lines will represent all subtypes and prognoses. As each line is characterized, the project team will make it available to the worldwide scientific community.
Hyperthermia – Stehlin researchers are continuing their pioneering research into the selective sensitivity of cancer cells to heat. One project will inject magnetic nanoparticles into nude mice carrying human tumors. The nanoparticles are attached to antibodies designed to seek out cancer cells. When exposed to radiofrequency waves, the nanoparticles absorb the energy and express it as heat, killing the tumor cells.
CHRISTUS Health, an international nonprofit healthcare system based in Dallas, became the Foundation’s sole corporate sponsor in 2006.
The Foundation’s fiscal year 2012 budget is $5.1 million. Unlike most cancer research institutions, sponsored primarily through medical schools and government grants, Stehlin receives 100 percent of its funding from individual donors, private foundations, and corporate partners.
Independent funding allows Stehlin scientists to focus solely on their work fighting cancer, speeding up the time from research bench to patient treatment, and continuing Dr. Stehlin’s legacy.
For more information about the Foundation and its research programs, please contact us at 713-659-1336. Tours of the laboratory are available by request.
November 23, 2013
Since its founding in 1997, Golfers Against Cancer has had one goal: to fund cancer research. Virtually all the money raised in GAC tournaments and events goes directly to cancer research organizations, including the CHRISTUS Stehlin Foundation.
August 2, 2013
The 14th Annual Luci Bonneau Memorial Striking Against Breast Cancer Mixed Doubles Bowling Tournament is one of the most prestigious doubles events in America. The tournament includes a Pro-Am - your chance to bowl with the pros to cure breast cancer!
October 19, 2013 | 7:00 p.m.
Get ready to disco and dance the night away at The Friends of CHRISTUS Stehlin Gala! Premiering “STAYIN’ ALIVE,” The Greatest Bee Gees Tribute Band with Members of the Houston Symphony Orchestra and America’s first Mash Up Group, “THE COMPANY MEN.”
May 4, 2013
On May 4th, 2013, young women will take the field for the first time in an exciting powder puff football game with teams comprised of some of best and brightest in Austin. The game is designed to bring the passion and spirit of young community leaders together to support Young Texans Against Cancer.
CHRISTUS Stehlin Foundation for Cancer Research will join CHRISTUS St. Catherine and CHRISTUS St. John in a new partnership with Houston Methodist.
There are currently 13.7 million cancer survivors in the United States and the number is expected to rise by 31 percent to 18 million by 2022, according to a new report. >> Click article title for more.